Home
Issues
2018
April 2018, Vol 7, No 1
2017
December 2017, Vol 6, No 5
October 2017, Vol 6, No 4
August 2017, Vol 6, No 3
June 2017, Vol 6, No 2
April 2017, Vol 6, No 1
2016
December 2016, Vol 5, No 6
October 2016, Vol 5, No 5
August 2016, Vol 5, No 4
June 2016, Vol 5, No 3
April 2016, Vol 5, No 2
February 2016, Vol 5, No 1
Issues Archive
Supplements
Categories
Web Exclusives
All Web Exclusives
FDA Approvals, News & Updates
In The News
Online First
Videos
About
About VBCR
About Engage HC
Contact Us
Editorial/Publishing Policies
Editorial Board
Advertising Contacts
Advertising Policy
Author Guidelines
Friday, 29 March 2024
Authored Items
Value and Cost-Effectiveness Analyses Should Be Included in Reimbursement Decisions
Kate Smith
VBCC - February 2015, ASH 2014 Highlights
in
Health Economics
The Hematology Pipeline Is Abundant
Kate Smith
,
Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights
in
Emerging Therapies
American-Style Capitalism Drives Drug Development: Cancer Therapies Targeting Small Subpopulations Dictate Prices
Kate Smith
VBCC - February 2015, ASH 2014 Highlights
in
Health Economics
Stem-Cell Mobilization More Cost-Effective with Plerixafor
Kate Smith
VBCC - February 2015, ASH 2014 Highlights
in
Health Economics
High Cancer Drug Prices Hurt Patients
Kate Smith
VBCC - February 2015, ASH 2014 Highlights
in
Health Economics
Financial Toxicity Impacts Treatment Adherence
Kate Smith
VBCC - February 2015, ASH 2014 Highlights
in
Health Economics
Onyx 360 Program Shown to Reduce Patient Distress
Kate Smith
VBCC - February 2015, ASH 2014 Highlights
in
Multiple Myeloma
Interim ASPIRE Results: Carfilzomib-Based Triplet Yields “Unprecedented” Remission Rates
Kate Smith
VBCC - February 2015, ASH 2014 Highlights
in
Multiple Myeloma
Monoclonal Antibodies Poised to Be “Blockbusters” in Myeloma
Kate Smith
VBCC - February 2015, ASH 2014 Highlights
in
Multiple Myeloma
Pomalidomide plus Low-Dose Dexamethasone Combination Likely to Be Cost-Effective
Kate Smith
VBCC - February 2015, ASH 2014 Highlights
in
Multiple Myeloma
Weekly Carfilzomib Safe and Effective
Kate Smith
VBCC - February 2015, ASH 2014 Highlights
in
Multiple Myeloma
Novel Oral Proteasome Inhibitor Oprozomib Shows Promise in Myeloma
Kate Smith
VBCC - February 2015, ASH 2014 Highlights
in
Multiple Myeloma
New Data on Ixazomib Maintenance Support Long-Term Oral Therapy in Patients with Myeloma
Kate Smith
VBCC - February 2015, ASH 2014 Highlights
in
Multiple Myeloma
Dissecting the Treatment Costs of Newly Diagnosed Myeloma in First 2 Years
Kate Smith
VBCC - February 2015, ASH 2014 Highlights
in
Multiple Myeloma
Last modified: February 26, 2015
Home
Issues
2018
April 2018, Vol 7, No 1
2017
December 2017, Vol 6, No 5
October 2017, Vol 6, No 4
August 2017, Vol 6, No 3
June 2017, Vol 6, No 2
April 2017, Vol 6, No 1
2016
December 2016, Vol 5, No 6
October 2016, Vol 5, No 5
August 2016, Vol 5, No 4
June 2016, Vol 5, No 3
April 2016, Vol 5, No 2
February 2016, Vol 5, No 1
Issues Archive
Supplements
Categories
Web Exclusives
All Web Exclusives
FDA Approvals, News & Updates
In The News
Online First
Videos
About
About VBCR
About Engage HC
Contact Us
Editorial/Publishing Policies
Editorial Board
Advertising Contacts
Advertising Policy
Author Guidelines